Pre-treatment activation of RDIs results in high CD8 + T cell infiltration levels in the TME reinforcing a hot tumor niche, albeit with a limited fraction of effector T cells due to checkpoint activation (Fig. 6 pre-treatment phase). This evidence concerns the gene CD8A and neoplasm.